FDA: Glaxo Vaccine Information Wrong
Product materials for several GlaxoSmithKline Plc hepatitis vaccines contain false information about flu vaccines that could lead to public health problems, U.S. regulators said in a letter released on Tuesday.
Hepatitis vaccines Havrix, Twinrix and Engerix-B all included the company’s version of general U.S. government vaccine guidelines but listed false flu vaccine recommendations, the U.S. Food and Drug Administration wrote.
Glaxo’s chart creates “a serious public health concern because it could lead to incorrect administration” of the live attenuated influenza vaccine to pregnant women with medical problems and very young children—for whom the drug has not been shown to be safe, the letter said.
The U.S. Centers for Disease Control and Prevention recommends flu vaccines for healthy people aged 5 to 49. The GlaxoSmithKline chart recommended the vaccine for children 6 months to 5 years old and for adults up to age 50, according to the FDA.
The wrong information was a particular concern because it “was distributed during the height of the flu season,” the agency also said.
Glaxo spokeswoman Amanda Foley said the British drugmaker thought the information “was in compliance with FDA policies. Any omissions and statements the FDA objected to were not intentional.”
The materials were distributed in late 2003 until early this year but have been discontinued, Foley said, adding that corrected information would be sent out.
Foley also said the company was reviewing all of its vaccine promotional materials to make sure they were FDA compliant.
The letter, which was dated July 6, was posted on Tuesday on the FDA Web site at [url=http://www.fda.gov]http://www.fda.gov[/url]
Materials for the hepatitis vaccines also failed to list critical safety warnings, including adverse reactions and medical conditions that should prevent some patients from getting the vaccine, the FDA said.
The agency sends dozens of similar warning letters each year. While most are resolved without regulatory action, the FDA can impose injunctions, fines and other penalties.
Revision date: December 21, 2007
Last revised: by Armen E. Martirosyan, M.D.
| RELATED STORIES: | ||
| Comments | [ + Post Your Own ] |
Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.
There are no comments for this entry yet. [ + Comment here + ]
We are pleased to let readers post comments about an article. Please increase the credibility of your post by including your full name and email.
All comments are reviewed by our editors before they are posted on the site. Just keep it clean, kids.
- Full Story - - »»»
Stimulus money to help build healthier Hub
- Full Story - - »»»
Omaha Gets Money to Fight Childhood Obesity
- Full Story - - »»»
Optimism about heart risks may be a good thing
- Full Story - - »»»
Rochester-Led Study Leads to Recommendation for Use of Heart Failure Treatment Nationwide
- Full Story - - »»»
Stress During Pregnancy May Increase Offspring’s Risk of Asthma
- Full Story - - »»»
Mom’s antidepressants may delay baby’s first steps
- Full Story - - »»»

